Articles: 30.10 October 2019

The UK’s ever-changing prescribing landscape

‘More’ is a well-used word when it comes to talking about prescribing. In primary care, there has been an approximate doubling of the number of prescriptions dispensed over 20 years or so. And it’s not just more pills being handed out, but more prescribers and …

More details...

Obsessive-compulsive disorder: current management options

Obsessive-compulsive disorder is a disabling condition that can severely affect daily activities in both adults and children. This article discusses the psychological and drug treatments available, and highlights instances where referral for specialised treatment is appropriate.
In everyday speech, someone may be described as ‘obsessive’ about …

More details...

Prescribing Simulator: new tool to develop prescribing skills

Gaining sufficient expertise on medicines and prescribing takes practice, which is ideally done in an environment that doesn’t involve actual patients. This is the function of the recently launched Prescribing Simulator, an e-learning project from the British Pharmacological Society. This article takes a look at …

More details...

Apalutamide for the treatment of non-metastatic prostate cancer

Apalutamide (Erleada) is a selective androgen-receptor inhibitor licensed for the treatment of non-metastatic castration-resistant prostate cancer in men who are at high risk of developing metastatic disease. This article discusses its properties, efficacy and side-effects

More details...

Diagnosis and treatment of eczema in children

Eczema, the clinical phenotype of atopic eczema/dermatitis, affects around 20% of pre-school age children in the UK. The disease manifests during the first year of life in 60% of patients but it can develop at any age. It can have a significant psychosocial impact on the child and their family. While eczema improves or resolves in up to 70% of children, markers of persistence are early onset, severe disease, family history and early allergen sensitisation

More details...

Suspected neurological conditions: when to refer

Earlier this year, NICE published a new guideline on the recognition and referral of patients with suspected neurological conditions (NG127), to help non-specialist healthcare professionals identify people who should be offered further specialist investigation. This article provides a brief summary of the guidance

More details...

Ertugliflozin: a new SGLT2 inhibitor for type 2 diabetes

Ertugliflozin (Steglatro) is a new sodiumglucose co-transporter-2 (SGLT2) inhibitor for the treatment of adults with type 2 diabetes. This article examines its place in therapy, clinical trial efficacy and adverse effects

More details...

Web design and marketing agency Leamington Spa